Marshall Wace
PDLI

Marshall Wace’s PDL BioPharma, Inc. PDLI Stock Holding History

Marshall Wace’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-165,921
Closed -$539K – 2294
2019
Q4 		$539K Sell
165,921
-78,580
-32% -$228K ﹤0.01% 1141
2019
Q3 		$528K Sell
244,501
-253,698
-51% -$678K ﹤0.01% 1095
2019
Q2 		$1.56M Buy
498,199
+455,193
+1,058% +$1.48M 0.01% 837
2019
Q1 		$160K Buy
+43,006
New +$145K ﹤0.01% 1363
2016
Q1 		– Sell
-46,678
Closed -$165K – 1348
2015
Q4 		$165K Sell
46,678
-108,922
-70% -$456K ﹤0.01% 928
2015
Q3 		$783K Buy
+155,600
New +$892K 0.01% 667

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's PDLI Position: Q1 2020 in Review

Marshall Wace sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 165,921 shares — an estimated $539K sold.

Marshall Wace first reported a position in PDLI in Q3 2015 and held it in 6 quarters. The position peaked at $1.56M in Q2 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Marshall Wace reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace sold 165,921 PDL BioPharma, Inc. shares in Q1 2020, an estimated $539K.
  • Marshall Wace first reported a position in PDL BioPharma, Inc. in Q3 2015 and held it in 6 quarters.
  • Marshall Wace's PDL BioPharma, Inc. position peaked at $1.56M in Q2 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Marshall Wace's 13F filing for Q1 2020, filed 15 May 2020.